Skip to main content

Table 5 The league table for results based on event frequency estimates agents for moderate HTG population according to their relative effects with odds ratio (95% confidence interval)

From: Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis

Bezafibrate (0.823)      0.56 (0.33–0.94)  
0.60 (0.34–1.05) Fenofibrate (0.290)     0.93 (0.74–1.17)  
0.78 (0.46–1.33) 1.30 (1.001.70) Icosapent Ethyl (0.675)    0.72 (0.620.82)  
0.58 (0.32–1.05) 0.97 (0.66–1.41) 0.74 (0.53–1.04) Niacin (0.244)   0.97 (0.71–1.31)  
1.80 (0.07–47.78) 2.99 (0.12–77.15) 2.30 (0.09–58.97) 3.10 (0.12–80.45) Omega-3 fatty acid (0.715) 0.31 (0.01–7.96)  
0.56 (0.33–0.94) 0.93 (0.74–1.17) 0.72 (0.620.82) 0.97 (0.71–1.31) 0.31 (0.01–7.96) Placebo (0.161) 1.33 (1.011.75)
0.74 (0.41–1.33) 1.24 (0.86–1.77) 0.95 (0.70–1.29) 1.28 (0.85–1.94) 0.41 (0.02–10.68) 1.33 (1.011.75) Pravastatin (0.593)
  1. HTG hypertriglyceridemia
  2. Italic font means statistical difference. Traditional pairwise at upper right side, network pairwise at lower left side
  3. #The P-score is performed in brackets